Alzheimer's disease (AD) will become a public health crisis within the next 2-3 decades if left unchecked. There are no proven treatments that delay the onset or prevent the progression of AD, although several promising candidates are being developed. During the development of these therapies, it will be very important to have biomarkers that can identify individuals at high risk for AD in eariiest clinical stages in order to target them for clinical trials of disease-modifying therapies and to monitor therapy success. Clinicopathologic evidence suggests that AD pathology (particularly the buildup of amyloid plaques) begins 10-20 years before the onset of cognitive symptoms. The earliest clinical symptoms of AD are accompanied by, and likely due to, neuronal and synaptic dysfunction and/or cell death. Thus, it will be critical to identify individuals with """"""""preclinical"""""""" and very early stage symptomatic AD, prior to marked clinical symptoms and neuron loss, so new therapies will have the greatest chance to preserve normal brain function. The Adult Children Study (ACS) Biomarker Core was initially funded as a competitive supplement to the ACS PPG in April 2008. The Core's mission is to facilitate and support antecedent AD biomarkers research by providing the necessary infrastructure for the collection, storage, and dissemination of fluid (CSF and plasma) samples (and associated data) for our own research at Washington University and that of the greater AD scientific community. Since inception of the Core, our productivity has roughly doubled (as defined by the number of CSF and plasma samples collected, the number of samples disseminated to investigators, and the number of papers using our samples that have been published in peer-reviewed journals). Thus, in the present renewal application, we propose to build upon our success and propose the following aims:
Aim 1 : Maintain and grow a repository of fasted CSF and plasma samples for present and future aging and AD biomarker studies.
Aim 2 : Coordinate the distribution of CSF and plasma samples to qualified investigators.
Aim 3 : Compare the values obtained for CSF Ap42, tau and ptauiei in Project 2 as a function of assay (Innotest vs. xMAP) and plasma Ap species (APi^o, APx-40, APi.42. APx^2) as a function of fasting state.
There are currently no effective treatments that will prevent Alzheimer's disease, halt its progression or delay its onset, although several therapeutic approaches are being developed and tested in clinical trials. Parallel efforts are being channeled into developing biomarkers that would aid in disease diagnosis and prognosis and assessing disease risk. Together these combined endeavors have the potential to provide physicians the tools to effectively diagnose and treat the disease, preferably everi before the onset of cognitive decline.
|Roe, Catherine M; Ances, Beau M; Head, Denise et al. (2018) Incident cognitive impairment: longitudinal changes in molecular, structural and cognitive biomarkers. Brain 141:3233-3248|
|Ihara, Ryoko; Vincent, Benjamin D; Baxter, Michael R et al. (2018) Relative neuron loss in hippocampal sclerosis of aging and Alzheimer's disease. Ann Neurol 84:741-753|
|Sutphen, Courtney L; McCue, Lena; Herries, Elizabeth M et al. (2018) Longitudinal decreases in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer's disease. Alzheimers Dement 14:869-879|
|Xiong, Chengjie; Luo, Jingqin; Chen, Ling et al. (2018) Estimating diagnostic accuracy for clustered ordinal diagnostic groups in the three-class case-Application to the early diagnosis of Alzheimer disease. Stat Methods Med Res 27:701-714|
|Gabel, Matthew; Gooblar, Jonathan; Roe, Catherine M et al. (2018) Political Ideology, Confidence in Science, and Participation in Alzheimer Disease Research Studies. Alzheimer Dis Assoc Disord 32:179-184|
|Roe, Catherine M; Babulal, Ganesh M; Mishra, Shruti et al. (2018) Tau and Amyloid Positron Emission Tomography Imaging Predict Driving Performance Among Older Adults with and without Preclinical Alzheimer's Disease. J Alzheimers Dis 61:509-513|
|Musiek, Erik S; Bhimasani, Meghana; Zangrilli, Margaret A et al. (2018) Circadian Rest-Activity Pattern Changes in Aging and Preclinical Alzheimer Disease. JAMA Neurol 75:582-590|
|Aschenbrenner, Andrew J; Gordon, Brian A; Benzinger, Tammie L S et al. (2018) Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease. Neurology 91:e859-e866|
|Day, Gregory S; Gordon, Brian A; Perrin, Richard J et al. (2018) In vivo [18F]-AV-1451 tau-PET imaging in sporadic Creutzfeldt-Jakob disease. Neurology 90:e896-e906|
|Lewczuk, Piotr; Riederer, Peter; O'Bryant, Sid E et al. (2018) Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World J Biol Psychiatry 19:244-328|
Showing the most recent 10 out of 352 publications